Table 1 Demographics and patient disposition by treatment groups.

From: Pharmacokinetic–pharmacodynamic guided optimisation of dose and schedule of CGM097, an HDM2 inhibitor, in preclinical and clinical studies

Demographic variables

10 mg Reg 1, N = 3

20 mg Reg 1, N = 4

40 mg Reg 1, N = 4

80 mg Reg 1, N = 4

150 mg Reg 1, N = 4

300 mg Reg 1, N = 7

400 mg Reg 1, N = 5

300 mg Reg 3, N = 8

500 mg Reg 3, N = 6

700 mg Reg 3, N = 6

All patients, N = 51

Age (years)

 Mean (SD)

47 (8.89)

50 (9.13)

50.8 (13.65)

59.3 (5.38)

44.5 (7.0)

58.7 (7.67)

56.8 (12.05)

50.3 (12.51)

56.3 (11.55)

56.7 (8.26)

53.6 (10.33)

Age group (years), n (%)

 <65

3 (100)

4 (100)

3 (75.0)

3 (75.0)

4 (100)

5 (71.4)

3 (60.0)

7 (87.5)

5 (83.3)

5 (83.3)

42 (82.4)

 ≥65

0

0

1 (25.0)

1 (25.0)

0

2 (28.6)

2 (40.0)

1 (12.5)

1 (16.7)

1 (16.7)

9 (17.6)

Sex, n (%)

 Male

1 (33.3)

3 (75.0)

3 (75.0)

2 (50.0)

1 (25.0)

2 (28.6)

2 (40.0)

3 (37.5)

2 (33.3)

3 (50.0)

22 (43.1)

 Female

2 (66.7)

1 (25.0)

1 (25.0)

2 (50.0)

3 (75.0)

5 (71.4)

3 (60.0)

5 (62.5)

4 (66.7)

3 (50.0)

29 (56.9)

WHO PS, n (%)

 0

2 (66.7)

3 (75.0)

3 (75.0)

2 (50.0)

2 (50.0)

4 (57.1)

4 (80.0)

4 (50.0)

3 (50.0)

4 (66.7)

31 (60.8)

 1

0

1 (25.0)

0

1 (25.0)

2 (50.0)

2 (28.6)

1 (20.0)

4 (50.0)

3 (50.0)

2 (33.3)

16 (31.4)

 2

1 (33.3)

0

1 (25.0)

1 (25.0)

0

1 (14.3)

0

0

0

0

4 (7.8)

Patient disposition, n (%)

 Treatment discontinued

3 (100)

4 (100)

4 (100)

4 (100)

4 (100)

6 (85.7)

4 (80.0)

8 (100)

6 (100)

6 (100)

49 (96.1)

 Treatment ongoing

0

0

0

0

0

1 (14.3)

1 (20.0)

0

0

0

2 (3.9)

Primary reason for treatment end, n (%)

 Adverse event

0

0

0

0

0

1 (14.3)

2 (40.0)

1 (12.5)

0

1 (16.7)

5 (9.8)

 Consent withdrawn

0

0

0

0

0

0

0

0

0

1 (16.7)

1 (2.0)

 Death

1 (33.3)

0

1 (25.0)

0

0

0

0

0

0

0

2 (3.9)

 Disease progression

2 (66.7)

4 (100)

3 (75.0)

4 (100)

4 (100)

5 (71.4)

2 (40.0)

7 (87.5)

6 (100)

4 (66.7)

41 (80.4)

  1. Reg regimen, PS performance status.
  2. Reg 1: 3qw dosing, 4-week treatment cycle, continuous; Reg 3: 3qw dosing, 3-week treatment cycle; 2 weeks on treatment and 1 week off treatment.